A Missouri judge on Friday granted final approval to Bayer's $7.25 billion nationwide class settlement resolving current and future lawsuits alleging that the weedkiller Roundup causes cancer, a decision that could finally close a decade of litigation that has weighed on the German company since it bought Monsanto in 2018.

Source: Reuters

St. Louis Circuit Judge Timothy Boyer approved the settlement in a written judgment on Friday, November 20, 2026, rejecting numerous objections. He called the average individual payouts “fair and adequate” and said the total amount is “among the largest in the history of mass tort personal-injury class action settlements.”

Source: Associated Press

What the settlement covers

The settlement, announced in February, covers people in the United States who were exposed to Roundup or other glyphosate-based products before February 17, 2026, and developed non-Hodgkin lymphoma, a form of blood cancer. It applies both to people who are already ill and to those diagnosed in the future.

It has two subclasses: people who already have a non-Hodgkin lymphoma diagnosis, and people who receive such a diagnosis before the end of a 16-year period following final approval. Payouts range from $10,000 to $165,000, depending on how the person used the product, how old they were when diagnosed and how severe their illness is. The settlement also includes $600 million for attorneys’ fees.

To fund it, Monsanto will make declining capped annual payments for up to 21 years, totalling as much as $7.25 billion, including payments already made. Bayer said the settlement, combined with the US Supreme Court’s June ruling in the Durnell case, is designed to significantly contain the Roundup litigation.

Bayer calls it a milestone — and still denies the cancer link

Bayer chief executive Bill Anderson called the approval “a decisive milestone in the company’s strategy to mitigate the risks of both pending and future Roundup litigation.” Bayer continues to deny that Roundup causes cancer, and Monsanto said it will keep defending cases and applying the Durnell ruling. The final approval order is subject to appeal.

A decade of litigation

Monsanto debuted Roundup in 1974, with the chemical glyphosate as its active ingredient. Bayer added the weedkiller to its portfolio when it acquired Monsanto in 2018, inheriting tens of thousands of lawsuits from people who blame Roundup for their cancers. The litigation has cost Bayer billions of dollars, driven down its share price and at one point led it to consider pulling the product from US agricultural markets.

The legal landscape shifted in June, when the US Supreme Court ruled 7-2 in Monsanto v. Durnell that federal pesticide law pre-empts state “failure-to-warn” claims that would require a cancer warning the federal government has not required. Judge Boyer cited that ruling in finding the settlement adequate.

Earlier: Monsanto wins the Aretino verdict

On October 29, a St. Louis County jury returned a unanimous defence verdict in Aretino v. Monsanto — the first Roundup case to go to trial since the Durnell decision. Friday’s settlement approval follows that verdict. Read the earlier report

What it means for farmworkers and families

The settlement matters most to the people who actually handled the product — farmers, landscapers and groundskeepers, including many immigrant workers in American agriculture. Anyone exposed before February 17, 2026, who has developed or later develops non-Hodgkin lymphoma may be covered by the long-term claims programme, regardless of the legal theory behind their claim.

$7.25 billionMaximum settlement value
21 yearsMaximum payment period
$10,000–$165,000Individual payout range
1974Year Monsanto debuted Roundup

What happens next

The long-term claims programme will now open for current and future claimants, and the approval order can be appealed. Bayer says it will continue to defend remaining cases. Families who used Roundup should keep records of their exposure and watch for the claims programme’s deadlines and filing details as they are published.